In a multisociety clinical practice guidance document, published online Oct. 29 in Surgery for Obesity and Related Diseases, ...
Only 13 states currently allow Medicaid to cover treatment of obesity using glucagon-like peptide-1 agonist (GLP-1) ...
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can decrease the risk for developing early-onset colorectal cancer ...
You can’t go far lately without seeing news and social media coverage of GLP-1 (glucagon-like peptide-1) receptor agonists ...
The use of glucagon-like peptide 1 (GLP-1) agonists in patients with inflammatory bowel disease (IBD) was associated with few ...
Only 13 states currently allow Medicaid to cover treatment of obesity using glucagon-like peptide-1 agonist (GLP-1) ...
They focused on 12 studies with behavioral interventions (mainly diets with modest energy deficits), nine trials that used ...
The Denmark-based drug maker Zealand Pharma said Tuesday that its experimental weight-loss drug could help patients lose ...
For adolescents with obesity, GLP1-RA treatment is associated with a reduced risk for suicidal ideation or attempts.
Health News // 4 hours ago Medicaid covers GLP-1 weight-loss drugs in just 13 states Only 13 states currently allow Medicaid ...
Glucagon-like peptide-1 (GLP-1) receptor analogs are drugs that mimic fullness hormone GLP-1 and have been shown to reduce appetite, slow digestion, help stabilize blood sugar levels and impact ...